Abstract
Structural alterations of two schistosomicides (hycanthone and niridazole) can bring about very marked reductions in mutagenic activity without decreasing antischistosomal potency. Therefore, these two effects are not necessarily associated with each other, providing opportunities for the design and development of safer schistosomicidal drugs.